CD8A and posterior cortical atrophy: To better evaluate the potential efficacy of our new vaccine approach in patients, we used an HLA-A*02:01 ILL DextramerTM (Immudex, Copenhagen, Denmark) to assess the prevalence of HLA-A*02:01 ILL-specific CD8+ T cells in PBMCs from a cohort of 16 patients with PCa, 5 individuals with diagnosed benign prostate disease, and 4 healthy individuals (Table A3).